The National Alopecia Areata Foundation (NAAF) and the American Hair Research Society (AHRS) have issued the first U.S. guidelines for managing severe alopecia areata, recommending FDA-approved oral Janus kinase (JAK) inhibitors as the primary first-line therapy. The consensus statement, published in JAMA Dermatology, advises patients with severe alopecia areata to receive uninterrupted treatment with oral JAK inhibitors for at least six months to achieve sustained progress.
Key Treatment Recommendations
The guidelines define severe alopecia areata as 50% to 100% scalp hair loss, with mild and moderate cases categorized as ≤ 20% and 21% to 49% scalp hair loss, respectively. Disease severity is further upgraded in mild or moderate cases if patients experience a negative impact on quality of life, eyebrow or eyelash loss, or insufficient response after six months of treatment. For severe cases, the panel emphasizes continuous use of the same drug and dose to avoid relapse, which can occur within months of discontinuation or dose reduction.
Dr. Victor Quan, a board-certified dermatologist not involved in the guideline development, noted that prior to these recommendations, patients often underwent multiple failed treatments before gaining insurance coverage for oral JAK inhibitors. “This justifies [treatment choices to] insurance and provides reassurance to patients and other practicing dermatologists that oral JAK inhibitors are the single best treatment for severe AA,” he said.
The panel recommends FDA-approved oral JAK inhibitors such as baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) over off-label alternatives due to verified safety and efficacy data. Treatment decisions should be made after 6–12 months of therapy using shared decision-making, with objective measures like the Severity of Alopecia Tool (SALT) score and Alopecia Areata Scale (AASc) guiding response evaluation. Partial responders with ≥30% scalp hair regrowth may benefit from extending therapy to 12 months, as studies suggest such progress can lead to near-complete regrowth.
Alternative and Adjunctive Therapies
For patients with severe alopecia areata and concurrent atopic conditions, dupilumab (Dupixent) is a suitable alternative. The guidelines also endorse adjunctive therapies tailored to specific hair-loss patterns, including oral and topical minoxidil, intralesional corticosteroids, and high-potency topical steroids. Short-term oral corticosteroids (under 30 days) or pulse therapy may be used as a bridge, while topical prostaglandins and topical JAK inhibitors can address eyebrow, eyelash, or beard hair loss.
Related Post: Menin inhibitors show promise in AML treatment
Dr. Debra Jaliman, a board-certified dermatologist, advised baseline blood tests to assess anemia, white blood cell counts, kidney and liver function, and cholesterol levels before initiating treatment. She also highlighted the importance of reviewing patients’ histories for blood clots, heart disease, smoking, and cancer due to the safety warnings associated with JAK inhibitors.
The guidelines acknowledge that some patients may not respond adequately within the initial evaluation period. In such cases, clinicians may increase the dose, switch to a different oral JAK inhibitor, or adjust supplemental therapies. Dr. Quan explained that patients who fail one JAK inhibitor often achieve success with another, particularly those showing early regrowth in eyebrows, eyelashes, or ≥30% scalp hair by six months.
Therapies Not Recommended for Severe Cases
The guidelines explicitly do not recommend traditional systemic treatments for severe alopecia areata, including methotrexate, mycophenolate mofetil, hydroxychloroquine, azathioprine, cyclosporine, and various dietary supplements. These therapies lack sufficient evidence for efficacy in severe cases and may carry unnecessary risks compared to FDA-approved oral JAK inhibitors. Additionally, high-dose oral corticosteroids beyond 30 days or prolonged low-dose systemic steroids are excluded due to safety concerns. Other excluded treatments encompass excimer laser therapy, UV phototherapy, and ezetimibe-simvastatin. The panel also reached no consensus on including antihistamines, anthralin, intramuscular corticosteroids, topical immunotherapy, low-level light therapy, platelet-rich plasma injections, inosiplex, and interleukin-2. These disagreements highlight the need for further research to clarify their roles in severe alopecia management.
Unanswered Questions and Future Research
Dr. Quan emphasized unresolved questions, such as optimal JAK inhibitor tapering protocols and methods to fully capture alopecia’s impact on patients beyond scalp hair loss. He also raised the need for standardized laboratory safety monitoring guidelines and insights into which oral JAK inhibitors work best for individual patients. When dupilumab should be used in severe alopecia with atopy remains unclear.
Dr. Jaliman highlighted the importance of psychiatric referrals and connections to patient advocacy groups like NAAF for additional support. She also advised documenting medical necessity for cranial prostheses and camouflage to secure insurance coverage.